{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:17Z","timestamp":1793813957732,"version":"4.6.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We report the open-label extension (OLE) of the GO-AHEAD study evaluating the long-term efficacy and safety of golimumab (GLM) in patients with non-radiographic axial spondyloarthritis (nr-axSpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients [both GLM- and placebo (PBO)-treated in the double-blind phase] received GLM 50\u2009mg every 4\u2009weeks during the OLE (36-week treatment; additional 8-week safety follow-up; GLM\/GLM and PBO\/GLM groups). All patients who entered and received \u22651 dose of study treatment in the OLE were included in the efficacy and safety analyses. The primary efficacy evaluations were the proportions of patients achieving 20% and 40% improvement in the ASAS criteria (ASAS20 and ASAS40, respectively). Responders\u2019 analyses were calculated using a non-responder imputation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 198 patients randomised, 189\/198 (95.5%) entered the OLE; 174\/198 patients (87.9%) completed all visits. Although the proportion of responders increased from week 16 to week 52 in the OLE in both GLM\/GLM and PBO\/GLM groups, the GLM\/GLM group had a higher proportion of responders than the PBO\/GLM group throughout the OLE from week 16 to week 52 (ASAS20: 71.1% to 83.9% vs 40.0% to 75.0%, respectively; ASAS40: 56.7% to 76.3% vs 23.0% to 59.4%, respectively; ASAS partial remission: 33.0% to 53.8% and 18.0% to 45.8%). In the OLE, the overall incidence of AEs was lower in the GLM\/GLM vs PBO\/GLM groups (41.9% and 54.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sustained improvement in clinical efficacy was observed at 52\u2009weeks in patients with nr-axSpA following GLM treatment. GLM was well tolerated and provided substantial long-term benefits to patients with nr-axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT01453725; United States National Library of Medicine clinical trials database; www.clinicaltrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab346","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T21:09:55Z","timestamp":1618607395000},"page":"617-627","source":"Crossref","is-referenced-by-count":6,"title":["Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Rheumatology Department \u2013 H\u00f4pital Cochin, Universit\u00e9 de Paris, Assistance Publique \u2013 H\u00f4pitaux de Paris, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cit\u00e9. Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Bergman","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P","family":"Curtis","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjela","family":"Tzontcheva","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Huyck","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-7232","authenticated-orcid":false,"given":"George","family":"Philip","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectiology and Rheumatology, University Clinic Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"2022020819094180900_keab346-B1"},{"key":"2022020819094180900_keab346-B2"},{"key":"2022020819094180900_keab346-B3","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022020819094180900_keab346-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B5","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF\u03b1 treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B6","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2022020819094180900_keab346-B7","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2022020819094180900_keab346-B8","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2022020819094180900_keab346-B9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B10","first-page":"1609","article-title":"A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI)","volume":"22","author":"Jones","year":"1995","journal-title":"J Rheumatol"},{"key":"2022020819094180900_keab346-B11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B12","first-page":"S72","article-title":"Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS)","volume":"42","author":"Helliwell","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2022020819094180900_keab346-B13","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware Jr","year":"1993"},{"key":"2022020819094180900_keab346-B14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","article-title":"Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D)","volume":"36","author":"Hurst","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2022020819094180900_keab346-B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2022020819094180900_keab346-B16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022020819094180900_keab346-B18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology"},{"key":"2022020819094180900_keab346-B20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B21","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/rheumatology\/kex081","article-title":"Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"key":"2022020819094180900_keab346-B22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022020819094180900_keab346-B23","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol Suppl"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab346\/38608936\/keab346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/617\/42368856\/keab346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/617\/42368856\/keab346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T14:12:06Z","timestamp":1644329526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/2\/617\/6241067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4,20]]},"published-print":{"date-parts":[[2022,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab346","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,4,20]]}}}